[Efficacy and safety of roxadustat in the treatment of refractory non-severe aplastic anemia].
Zhonghua Xue Ye Xue Za Zhi
; 45(3): 264-270, 2024 Mar 14.
Article
en Zh
| MEDLINE
| ID: mdl-38716598
ABSTRACT
Objective:
To evaluate the efficacy and safety of roxadustat in patients with refractory non-severe aplastic anemia (NSAA) .Methods:
The clinical data of patients with refractory NSAA who had been treated with roxadustat continuously for at least 3 months and followed up for more than 6 months at Peking Union Medical College Hospital from October 2020 to August 2022 were retrospectively collected. The demographic information, clinical data, treatment efficacy, adverse reactions, and outcomes were evaluated, and the factors influencing efficacy were analyzed.Results:
A total of 41 patients were included. The male-to-female ratio was 16â¶25, and the median age was 52 (18-84) years. The median duration of roxadustat treatment was 5 (3-20) months, and the median follow-up was 15 (6-26) months. Hematologic improvement-erythroid (HI-E) was 12.2%, 29.3%, 46.3%, 43.9%, and 30.3% at 1, 2, 3, 6, and 12 months, respectively. The rate of transfusion independence was 28.5%, 38.1%, and 33.3% at 3, 6, and 12 months, respectively. Hemoglobin returned to normal in some patients after treatment with roxadustat. The incidence of adverse events was 22%, all of which were grade â -â ¡ and recoverable. No factors that could affect HI-E were identified. By the end of follow-up, 45% of the patients relapsed, with a median time to relapse of 7 (3-12) months. No clonal evolution was observed, and one patient died.Conclusion:
Roxadustat effectively improved anemia with good tolerance in patients with refractory NSAA.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Glicina
/
Anemia Aplásica
/
Isoquinolinas
Límite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Zh
Revista:
Zhonghua Xue Ye Xue Za Zhi
Año:
2024
Tipo del documento:
Article
País de afiliación:
China